Ashish R Kumar
Overview
Explore the profile of Ashish R Kumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1099
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henter J, Sieni E, Eriksson J, Bergsten E, Hed Myrberg I, Canna S, et al.
Blood
. 2024 Jul;
144(22):2308-2318.
PMID: 39046779
Current hemophagocytic lymphohistiocytosis 2004 (HLH-2004)-based diagnostic criteria for familial hemophagocytic lymphohistiocytosis (FHL) are based on expert opinion. Here, we performed a case-control study to test and possibly improve these criteria....
2.
Hashem H, Bucciol G, Ozen S, Unal S, Bozkaya I, Akarsu N, et al.
J Clin Immunol
. 2022 May;
42(7):1580-1581.
PMID: 35499644
No abstract available.
3.
Kemps P, Picarsic J, Durham B, Helias-Rodzewicz Z, Hiemcke-Jiwa L, van den Bos C, et al.
Blood
. 2021 Nov;
139(2):256-280.
PMID: 34727172
ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been...
4.
Hashem H, Bucciol G, Ozen S, Unal S, Bozkaya I, Akarsu N, et al.
J Clin Immunol
. 2021 Jul;
41(7):1633-1647.
PMID: 34324127
Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an inherited inborn error of immunity, characterized by autoinflammation (recurrent fever), vasculopathy (livedo racemosa, polyarteritis nodosa, lacunar ischemic strokes, and intracranial hemorrhages),...
5.
Khandelwal P, Teusink-Cross A, Kumar A, Bleesing J, Mehta P, Jordan M, et al.
Br J Haematol
. 2021 May;
194(5):e84-e89.
PMID: 34046889
No abstract available.
6.
Gracia-Maldonado G, Clark J, Burwinkel M, Greenslade B, Wunderlich M, Salomonis N, et al.
Haematologica
. 2021 Apr;
107(4):803-815.
PMID: 33910331
Although great advances have been made in understanding the pathobiology of mixed lineage leukemia-rearranged (MLL-r) leukemias, therapies for this leukemia have remained limited, and clinical outcomes remain bleak. In order...
7.
Wang Y, Teusink-Cross A, Elborai Y, Krupski M, Nelson A, Grimley M, et al.
Transplantation
. 2021 Apr;
106(2):412-419.
PMID: 33795598
Background: Ruxolitinib, a JAK1/2 inhibitor, is used to treat chronic graft versus host disease (cGVHD) in adult allogeneic hematopoietic stem cell transplant patients, but experience in children is limited, perhaps...
8.
Foley C, Al Remeithi S, Towe C, Dauber A, Backeljauw P, Tyzinski L, et al.
J Clin Immunol
. 2020 Oct;
41(1):136-146.
PMID: 33090292
Patients with rare homozygous mutations in signal transducer and activator of transcription 5B (STAT5B) develop immunodeficiency resulting in chronic eczema, chronic infections, autoimmunity, and chronic lung disease. STAT5B-deficient patients are...
9.
Chandra S, Chandrakasan S, Davila Saldana B, Bleesing J, Jordan M, Kumar A, et al.
J Clin Immunol
. 2020 Oct;
41(1):89-98.
PMID: 33067658
Purpose: A need exists for reduced toxicity conditioning regimens that offer less toxicity while maintaining myeloablation, especially for primary immune deficiencies where myeloablation or high donor myeloid chimerism is required...
10.
Itskovich S, Gurunathan A, Clark J, Burwinkel M, Wunderlich M, Berger M, et al.
Nat Commun
. 2020 Jul;
11(1):3468.
PMID: 32636368
An amendment to this paper has been published and can be accessed via a link at the top of the paper.